A61K 38/193
Colony stimulating factors [csf]
Official title: {Colony stimulating factors [CSF]}
A61K38/193 (Colony stimulating factors [csf]) appears on 1,183 US grants and 2,076 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,183
- Published applications
- 2,076
- Assignees
- 814
- Inventors
- 2,793
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 3 | 0 |
| 1992 | 3 | 0 |
| 1993 | 6 | 0 |
| 1994 | 12 | 0 |
| 1995 | 2 | 0 |
| 1996 | 7 | 0 |
| 1997 | 15 | 0 |
| 1998 | 27 | 0 |
| 1999 | 17 | 0 |
| 2000 | 22 | 0 |
| 2001 | 18 | 11 |
| 2002 | 19 | 39 |
| 2003 | 18 | 43 |
| 2004 | 22 | 70 |
| 2005 | 27 | 86 |
| 2006 | 14 | 68 |
| 2007 | 21 | 93 |
| 2008 | 18 | 74 |
| 2009 | 21 | 81 |
| 2010 | 42 | 106 |
| 2011 | 41 | 76 |
| 2012 | 56 | 83 |
| 2013 | 45 | 88 |
| 2014 | 58 | 125 |
| 2015 | 68 | 115 |
| 2016 | 72 | 123 |
| 2017 | 67 | 88 |
| 2018 | 60 | 81 |
| 2019 | 51 | 79 |
| 2020 | 64 | 92 |
| 2021 | 42 | 92 |
| 2022 | 64 | 112 |
| 2023 | 45 | 89 |
| 2024 | 33 | 73 |
| 2025 | 57 | 49 |
| 2026 | 25 | 40 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method of treating SCLC and managing neutropenia29 Sep 2026US 12,746,240 B2Pharma Mar, S. A.
- Methods of treating small cell lung cancer with lurbinectedin formulations25 Aug 2026US 12,714,706 B2Pharma Mar, S. A.
- Methods of administering chimeric antigen receptor immunotherapy25 Aug 2026US 12,715,925 B2Kite Pharma, Inc.
- Methods of administering chimeric antigen receptor immunotherapy18 Aug 2026US 12,709,639 B2Kite Pharma, Inc.
- Treatment using oncolytic virus21 Jul 2026US 12,685,767 B2Replimune Limited
- Methods for stem cell transplantation1 Oct 2026US 2026/0294975 A1The UAB Research Foundation
- Humoral modulation in vaccinated and virally infected subjects with granulocyte-macrophage colony-stimulating factor (gm-csf)1 Oct 2026US 2026/0295009 A1Partner Therapeutics, Inc.
- Patrolling monocyte cellular therapy1 Oct 2026US 2026/0297525 A1New York Blood Center, Inc.
- Viral infection modulation in vaccinated subjects treated with granulocyte-macrophage colony-stimulating factor (gm-csf)20 Aug 2026US 2026/0240950 A1Partner Therapeutics, Inc.
- Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction13 Aug 2026US 2026/0232681 A1Biomea Fusion, Inc.
Most cited
By later US patents
- Engineered nucleic acids and methods of use thereof372US 8,822,663 B2Moderna Therapeutics, Inc. · 2014
- Engineered nucleic acids encoding a modified erythropoietin and their expression312US 8,710,200 B2Moderna Therapeutics, Inc. · 2014
- Pulmonary administration of granulocyte colony stimulating factor245US 5,284,656 AAmgen Inc. · 1994
- Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling242US 5,811,097 AThe Regents of the University of California · 1998
- Human mesenchymal stem cells from peripheral blood221US 6,261,549 B1Osiris Therapeutics, Inc. · 2001